KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables (2016 - 2026)

NovoCure's Receivables history spans 13 years, with the latest figure at $61.4 million for Q1 2026.

  • On a quarterly basis, Receivables rose 51.15% to $61.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $61.4 million, a 51.15% increase, with the full-year FY2025 number at $66.5 million, up 62.93% from a year prior.
  • Receivables hit $61.4 million in Q1 2026 for NovoCure, down from $66.5 million in the prior quarter.
  • Over the last five years, Receivables for NVCR hit a ceiling of $101.0 million in Q1 2022 and a floor of $17.5 million in Q3 2022.
  • Historically, Receivables has averaged $59.8 million across 5 years, with a median of $65.1 million in 2023.
  • Biggest five-year swings in Receivables: skyrocketed 443.65% in 2022 and later tumbled 65.03% in 2024.
  • Tracing NVCR's Receivables over 5 years: stood at $28.2 million in 2022, then fell by 4.34% to $26.9 million in 2023, then soared by 51.47% to $40.8 million in 2024, then surged by 62.93% to $66.5 million in 2025, then decreased by 7.64% to $61.4 million in 2026.
  • Business Quant data shows Receivables for NVCR at $61.4 million in Q1 2026, $66.5 million in Q4 2025, and $92.5 million in Q3 2025.